Secondary infections in COVID-19 patients: A two-centre retrospective observational study
Introduction: We sought to evaluate secondary infections (SIs) in patients admitted to the intensive care unit (ICU) for COVID-19 with respect to incidence, causative pathogens, and clinical outcomes. Methodology: In this two-centre retrospective study, we analysed 146 patients (96 males, 50 fem...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2022-08-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/15637 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193197350780928 |
|---|---|
| author | Şirin Menekşe Seçil Deniz |
| author_facet | Şirin Menekşe Seçil Deniz |
| author_sort | Şirin Menekşe |
| collection | DOAJ |
| description |
Introduction: We sought to evaluate secondary infections (SIs) in patients admitted to the intensive care unit (ICU) for COVID-19 with respect to incidence, causative pathogens, and clinical outcomes.
Methodology: In this two-centre retrospective study, we analysed 146 patients (96 males, 50 females; median age, 64 years) admitted to the ICU with COVID-19 between March 26 and December 31, 2020. Inclusion criteria were an ICU admission for at least 48 hours and age beyond 18 years. Patients with and without SIs were compared and the impacts of SIs and carbapenem resistance on mortality were analysed.
Results: During ICU admission, 84 episodes of SIs developed in 58 patients (39.7%). A total of 104 isolates were recovered, with Gram-negative bacteria most frequent accounting for 74%. At least one carbapenem-resistant pathogen (n = 61) was recovered in 41 patients (70.1%). In multivariate analysis, the use of ECMO and an elevated procalcitonin level were significantly associated with the development of SIs. The mortality rate and the incidence of carbapenem resistance did not differ significantly in COVID-19 patients with and without SIs (p = 0.059 and p = 0.083, respectively).
Conclusions: The incidences of SIs and carbapenem resistance among COVID-19 patients were alarming, emphasizing stricter infection control measures in the ICU setting.
|
| format | Article |
| id | doaj-art-2f2943991ebb4a6b9b42aa9bc42baf0c |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2022-08-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-2f2943991ebb4a6b9b42aa9bc42baf0c2025-08-20T02:14:20ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802022-08-01160810.3855/jidc.15637Secondary infections in COVID-19 patients: A two-centre retrospective observational studyŞirin Menekşe0Seçil Deniz1Department of Infectious Diseases, Koşuyolu Kartal Heart Training and Research Hospital, İstanbul, TurkeyDepartment of Infectious Diseases, Pamukkale University School of Medicine, Denizli, Turkey Introduction: We sought to evaluate secondary infections (SIs) in patients admitted to the intensive care unit (ICU) for COVID-19 with respect to incidence, causative pathogens, and clinical outcomes. Methodology: In this two-centre retrospective study, we analysed 146 patients (96 males, 50 females; median age, 64 years) admitted to the ICU with COVID-19 between March 26 and December 31, 2020. Inclusion criteria were an ICU admission for at least 48 hours and age beyond 18 years. Patients with and without SIs were compared and the impacts of SIs and carbapenem resistance on mortality were analysed. Results: During ICU admission, 84 episodes of SIs developed in 58 patients (39.7%). A total of 104 isolates were recovered, with Gram-negative bacteria most frequent accounting for 74%. At least one carbapenem-resistant pathogen (n = 61) was recovered in 41 patients (70.1%). In multivariate analysis, the use of ECMO and an elevated procalcitonin level were significantly associated with the development of SIs. The mortality rate and the incidence of carbapenem resistance did not differ significantly in COVID-19 patients with and without SIs (p = 0.059 and p = 0.083, respectively). Conclusions: The incidences of SIs and carbapenem resistance among COVID-19 patients were alarming, emphasizing stricter infection control measures in the ICU setting. https://jidc.org/index.php/journal/article/view/15637COVID-19secondary infectionscarbapenem resistanceintensive care unit infections |
| spellingShingle | Şirin Menekşe Seçil Deniz Secondary infections in COVID-19 patients: A two-centre retrospective observational study Journal of Infection in Developing Countries COVID-19 secondary infections carbapenem resistance intensive care unit infections |
| title | Secondary infections in COVID-19 patients: A two-centre retrospective observational study |
| title_full | Secondary infections in COVID-19 patients: A two-centre retrospective observational study |
| title_fullStr | Secondary infections in COVID-19 patients: A two-centre retrospective observational study |
| title_full_unstemmed | Secondary infections in COVID-19 patients: A two-centre retrospective observational study |
| title_short | Secondary infections in COVID-19 patients: A two-centre retrospective observational study |
| title_sort | secondary infections in covid 19 patients a two centre retrospective observational study |
| topic | COVID-19 secondary infections carbapenem resistance intensive care unit infections |
| url | https://jidc.org/index.php/journal/article/view/15637 |
| work_keys_str_mv | AT sirinmenekse secondaryinfectionsincovid19patientsatwocentreretrospectiveobservationalstudy AT secildeniz secondaryinfectionsincovid19patientsatwocentreretrospectiveobservationalstudy |